Featured Story

The elephant in the classroom

Biopharma needs to address its workforce training methods

PM1911 WebLeadImage 295X269

The world can’t stop talking about biopharma’s scientific achievements, but the discussion often avoids the industry’s biggest potential buzzkill: a shortage of properly trained workers to manufacture these new drugs.There’s no denying that biopharma drugs will play a vital role in the future of medicine. Biologics make up about 40 percent of the over 16,000 drugs in the global pharma pipeline. These biologic hopefuls include drugs in new therapeutic areas, such as cell and gene therapy, that are igniting the industry on fire with their potential to treat the previously untreatable. The U.S. Food and Drug Administration estimated that by 2020, they will be…

Full Story

Pharma Manufacturing Exclusives

Fundamentals

Valuable educational content — from tutorials to reference guides —  for all pharmaceutical manufacturing professionals.

Research Zone

A collection of news stories highlighting advances in medical science and pharmaceutical R&D.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • The elephant in the biopharma classroom

    By Karen Langhauser, Chief Content Director

    The world can’t stop talking about biopharma’s scientific achievements, but the discussion often avoids the industry’s biggest potential buzzkill: a shortage of properly trained workers to manufacture these new drugs.There’s no denying that biopharma drugs will play a vital role in the…

    Full Story
  • How did the FDA do in 2019? Tell us what you think!

    As always, the FDA tackled major challenges in 2019 — from streamlining drug approvals to promoting data integrity, combatting drug shortages, fighting the opioid epidemic and more. How well did the agency fare? Our December cover story will take a close look at some of the biggest regulatory…

    Full Story
  • Product Focus: Manufacturing meets Industry 4.0

    By Meagan Parrish, Senior Editor

    There’s no question that pharma products have become more sophisticated in recent years — from tissue engineered medicines to targeted gene therapies. But despite these advances, many parts of the manufacturing process are still in need of a technology-driven upgrade.“Modern technology…

    Full Story
  • China’s single-use craze

    By Vicky (Qing) XIA, Senior Project Director, BioPlan Associates

    Recent years have witnessed a sturdy boom in the development of biologics, especially monoclonal therapeutics in China’s biopharma sector. New facilities are proliferating throughout the country. While almost all Chinese biopharma companies have traditionally relied on stainless steel bioreactors…

    Full Story
  • Why IIoT can make the pharma cold chain safer and more efficient

    By Sam Cece, Founder, President, & CEO of Swift Sensors

    The demands for pharmaceutical cold-chain capacity and compliance are on the rise. The global pharmaceutical industry is growing by 3-6 percent year over year, while temperature-controlled pharmaceutical product sales are growing at double the overall pharmaceutical industry rate. Meanwhile, only a…

    Full Story
  • Evolving risks in continuous manufacturing

    By Dan Brettler, Managing Director, Life Science and Technology Practice Leader, Conner Strong and Buckelew

    The adoption of continuous manufacturing systems has the potential to transform pharmaceutical drug production by increasing operational capacity and reducing exposure to many traditional vulnerabilities. But the transition from batch to continuous processes not only marks a shift in operations, it…

    Full Story

Latest Products